GlassScriptPhysician profile
Saifudin Hussein
NPI 1306025739
$5,721.14
in general payments reported to CMS, 2019-2025
32 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $194 · 2021: $667 · 2022: $913 · 2023: $682 · 2024: $1,253 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,446.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $586.51 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $575.19 | 2021-2025 | Eliquis, Camzyos |
| Amgen INC. | $482.99 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $453.48 | 2019-2020 | |
| Pfizer INC. | $388.75 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.00 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $349.12 | 2021-2025 | Verquvo, Belsomra |
| Astrazeneca Pharmaceuticals LP | $330.48 | 2021-2025 | Farxiga, Brilinta, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $302.80 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $253.61 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $189.00 | 2024 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $162.62 | 2021-2025 | |
| Boston Scientific Corporation | $149.49 | 2024-2025 | General - Vascular Intervention, Watchman Flx, Watchman |
| Atricure, INC. | $148.36 | 2021-2024 | |
| Biotronik INC. | $142.94 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $110.33 | 2021-2024 | Xarelto |
| Scpharmaceuticals INC. | $92.32 | 2023-2025 | |
| Medtronic, INC. | $84.94 | 2021 | |
| Amarin Pharma, INC. | $80.22 | 2020-2022 | |
| Esperion Therapeutics, INC. | $76.11 | 2022-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $72.88 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $53.68 | 2019-2023 | Opsumit |
| Bridgebio Pharma, INC. | $49.05 | 2025 | Attruby |
| Heartflow, INC. | $46.09 | 2024 | |
| Baxter Healthcare | $38.27 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $34.81 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $28.37 | 2025 | Assure Wcd |
| Lilly USA, LLC | $24.78 | 2025 | Zepbound, Mounjaro |
| G Medical Diagnostic Services, INC. | $17.51 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.05 | 2021 | |
| Ascensia Diabetes Care US INC. | $13.12 | 2023 | |
| Vapotherm INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saifudin Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.